Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

ZURICH (Reuters) - Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines, it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive ...

ZURICH (Reuters) - Roche said on Friday it launched a laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients, as very high demand for tests prompts the Swiss ...

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

ロシュ・ダイアグノスティックス株式会社（本社：東京都港区／代表取締役社長 兼 CEO：小笠原 信）は、感染症研究や対策に取り組む方々をたたえる、第2回「Roche Infectious Disease Award（ロシュ感染症アワード）」の募集を開始します。昨年より募集テーマを ...

INDIANAPOLIS, Dec. 16, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas® 6800/8800 systems version 2.0 and software version 2.0.1, following U.S.

ロシュ・ダイアグノスティックス株式会社（本社：東京都港区／代表取締役社長 兼 CEO：小笠原 信）は、ロシュグループ創立125周年および日本における検査薬事業50周年を記念し、一般の方向けの無料オンライントークイベント「LifeTalks Japan」を開催します。

The new cobas ® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems.